Published in the Journal of Clinical Oncology, a review paper authored by a multidisciplinary group of international experts in DNA Damage Response (DDR) and PARP inhibition
Published in the Journal of Clinical Oncology, a review paper authored by a multidisciplinary group of international experts in DNA Damage Response (DDR) and PARP inhibition
AstraZeneca.
AstraZeneca, Eisai, Genentech, Lilly, Merck, Novartis, Pfizer and Roche.
Artios Pharma Ltd.
AstraZeneca, Amgen, Novartis, Pfizer and Roche.
AstraZeneca, Clovis, Pfizer, Roche and Tesaro.
AstraZeneca, Apera, Clovis, MSD, Nucana, Novartis, Roche, Sierra Oncology and Tesaro.
AstraZeneca and Tesaro.
AstraZeneca, Clovis, Cristal Therapeutics, Pfizer, Roche and Seattle Genetics.
10 years of independent medical education in GI oncology
Journey through a patient case from testing and diagnosis to treatment and AE management
Looking beyond the obvious mutations in non-small-cell lung cancer
Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer
Maximising outcomes for patients with advanced CRC
Make decisions for your patient at two key stages in their journey